PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.15), may not compare to the analyst estimate of ($1.20). Revenue for the quarter came in at $7.48 million versus the consensus estimate of $2.97 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.